Marizyme (MRZM) Stock Price & Analysis

MRZM Stock Chart & Stats

$0.05$0.00(0.00%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $0.00 - $0.05
52-Week Range: $0.00 - $0.05
Previous Close: $0.05
Volume: 92
Average Volume (3M): 0
Market Cap: $132
Enterprise Value: $20.65T
Total Cash (Recent Filing): $63.73K
Total Debt (Recent Filing): $26.66M
Price to Earnings (P/E): 0.0
Beta: 11.88
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Marizyme News

Marizyme Initiates Asset Assignment Amid Severe Financial Distress

Marizyme ( ($MRZM) ) has provided an update. On April 9, 2026, Marizyme, Inc.’s board determined that transferring all or substantially all of the company’s assets through an assignment for

6M ago8K MRZM

Marizyme Inc. Wins FDA Nod for DuraGraft Storage Advancement

The latest update is out from Marizyme Incorporated (MRZM). Marizyme, Inc. has announced FDA clearance for room temperature storage of DuraGraft, enhancing its commercial prospects in the U.S. cardiac care

2y ago8K MRZM

Marizyme Announces Director Julie Kampf’s Resignation

Marizyme Incorporated (MRZM) has released an update to notify the public and investors about its officers. Julie Kampf has resigned from her position on the board of directors of Marizyme,

2y ago8K MRZM

MRZM FAQ

What was Marizyme’s price range in the past 12 months?

Marizyme lowest stock price was $0.00 and its highest was $0.05 in the past 12 months.

What is Marizyme’s market cap?

Marizyme’s market cap is $132.

When is Marizyme’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Marizyme’s earnings last quarter?

Marizyme released its earnings results on Dec 23, 2021. The company reported -$0.045 earnings per share for the quarter.

Is Marizyme overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Marizyme pay dividends?

Marizyme does not currently pay dividends.

What is Marizyme’s EPS estimate?

Marizyme’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Marizyme have?

Marizyme has 131,793,090 shares outstanding.

What happened to Marizyme’s price movement after its last earnings report?

Marizyme reported an EPS of -$0.045 in its last earnings report. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Marizyme?

Currently, no hedge funds are holding shares in MRZM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Marizyme

Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.

Marizyme (MRZM) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	7	3	7
Technical Analysis	1	1	3
Moving Averages	6	2	4

Technical Analysis >

Similar Stocks

Stocks similar to MRZM
Company	Price & Change	Follow
ELOXEloxx Pharmaceuticals
OGENOragenics
MBRXMoleculin Biotech
MBIOMustang Bio
GNPXGenprex

Compare MRZM Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft